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Summary
Objective: Recent in vitro studies showed that celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, protects human osteoarthritic cartilage
tissue from degeneration. The objective was to substantiate these beneﬁcial effects in an in vivo (clinical) study with celecoxib treatment of
patients with severe knee osteoarthritis (OA) and subsequent evaluation of cartilage tissue ex vivo.
Methods: Patients with knee OA were treated 4 weeks prior to total knee replacement surgery with either celecoxib 200 mg b.d., indomethacin
50 mg b.d., or received no treatment. During surgery cartilage and synovium were collected and analyzed in detail ex vivo.
Results: When compared to non-treated patients, patients treated with celecoxib showed signiﬁcant beneﬁcial effects on proteoglycan syn-
thesis, -release, and -content, conﬁrming the in vitro data. In the indomethacin group, no signiﬁcant differences were found compared to
the control group. On the contrary, a tendency towards a lower content and lower synthesis rate was found. In the treated groups prostaglan-
din-E2 levels were lower than in the control group, indicating COX-2 inhibition. Ex vivo release of interleukin-1b (IL-1b) and tumour necrosis
factor-a by synovial tissue was decreased by treatment with celecoxib, whereas in the indomethacin group only IL-1b release was decreased.
Conclusion: Using this novel approach we were able to demonstrate an in vivo generated chondrobeneﬁcial effect of celecoxib in patients with
end stage knee OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a slowly progressive degenerative
joint disorder, with a high prevalence, gradual degeneration
of articular cartilage, peri-articular bone changes and
secondary synovitis. Pain is the most important symptom
in patients with OA1e4. The ﬁrst choice for pharmacological
pain management in patients with OA, considering the
guidelines of the American College of Rheumatology
(ACR)5, is still acetaminophen. But more recent studies
indicate that, especially in patients with severe pain, non-
steroidal anti-inﬂammatory drugs (NSAIDs) are superior6.
Additionally, patients with OA show a greater preference
for NSAIDs7e9. More recently, the Osteoarthritis Research
Society International (OARSI) Guidelines Committee
agrees that NSAIDs, both non-selective and selective,
have a major role in the management of OA10.*Address correspondence and reprint requests to: Tineke N. de
Boer, M.Sc., Rheumatology & Clinical Immunology, University
Medical Center Utrecht, Room F02.127, P.O. Box 85500, 3508
GA Utrecht, The Netherlands. Tel: 31-088-755-9428; Fax: 31-
030-252-3741; E-mail: t.n.deboer-4@umcutrecht.nl
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482Anti-inﬂammatory and analgesic effects of NSAIDs are
mainly due to their ability to suppress cyclooxygenase
(COX), an enzyme involved in the production of prostaglan-
dins. The clinical efﬁcacy and side-effects with respect to
gastrointestinal (GI) problems of NSAIDs are mostly well
understood11,12. According the OARSI Guidelines Commit-
tee selective NSAIDs appear to be safer with respect to GI
toxicity and tolerance than non-selective NSAIDs10. Cardio-
vascular side-effects of the second generation NSAIDs, the
selective COX-2 inhibitors (Coxibs), became evident more
recently13e16. But also for the conventional NSAIDs this
has always been a concern17,18. Adverse effects of selec-
tive COX inhibitors on bone turnover/repair are still subject
of study19.
Another aspect of NSAIDs, still ignored by many, is their
direct possible (adverse) effects on cartilage. Direct effects
of NSAIDs on cartilage may be of importance in treatment of
joint diseases, speciﬁcally in prolonged treatment of joint
disease in which inﬂammation is only mild and secondary,
as in OA. These direct effects should be considered in
addition to GI effects and cardiovascular effects when
prescribing NSAIDs in clinical practice. Speciﬁcally in
case of chronic use in not primarily inﬂammation mediated
joint disease.
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are not consistent. Adverse effects have been reported
frequently but also beneﬁcial or neutral effects have been
reported in vitro and in animal in vivo studies20e22. A fre-
quently used NSAID that has been studied in the past
regarding its direct effects on cartilage is indomethacin.
Indomethacin shows principally negative results on the bio-
chemical parameters of cartilage in vitro21,23 and animal
studies24,25, but there are also studies that could not ﬁnd
any effect of indomethacin on cartilage26,27.
Data on the selective COX-2 inhibitors are scarce.
Recent in vitro data on celecoxib have shown positive
effects on cartilage of OA patients28e31. These studies
showed that celecoxib has favourable effects on the
turnover of proteoglycans of OA cartilage, especially by
diminishing the loss of proteoglycans from the matrix and
increasing the retention of newly formed proteoglycans.
To a lesser extend the synthesis of proteoglycans is inﬂu-
enced beneﬁcially.
The direct effects of NSAIDs on cartilage cannot be stud-
ied easily in clinical trials and, therefore, they are generally
ignored in clinical practice. Moreover, effects of NSAIDs on
inﬂammation32 shade their direct effects on cartilage. In
addition (intrinsic) cartilage changes, catabolic and
anabolic, are generally very slow processes in OA and eval-
uation of cartilage degeneration by imaging techniques is
still hampered by the limited sensitivity of these techniques.
Therefore, we used an approach in which in vivo treatment
is combined with ex vivo evaluation of the cartilage tissue.
By treating patients with NSAIDs shortly before joint
replacement surgery, signiﬁcant amounts of cartilage tissue
that have been exposed in vivo become available for ex
vivo biochemical and histochemical analyses. This gives
us the opportunity to study in a relatively short period, the
effects of NSAIDs on OA cartilage treated in vivo by use
of detailed ex vivo biochemical and histochemical analyses.
The aim of this study was to investigate the effects of
treatment of patients with severe knee OA with celecoxib
for 4 weeks, in comparison with the conventional NSAID
indomethacin, and with no treatment, on the biochemical
characteristics of the joint cartilage.
MethodsPATIENTSTwenty-eight patients with severe knee OA, who were eligible for total
knee replacement surgery, have been included between December 2004
and April 2005. Patients were treated at the University Medical Center of
Utrecht (UMCU), the Netherlands (n¼ 15); the Sint Franciscus Gasthuis
Hospital in Rotterdam, the Netherlands (n¼ 9) and the Diakonessenhuis
Hospital in Utrecht, the Netherlands (n¼ 4).
Exclusion criteria were a total knee replacement for other reasons than
OA, patients with a history of GI bleedings or perforation, and patients with
an increased risk for cardiovascular diseases (patients with a history of car-
diovascular disease, with untreated hypertension, with angina pectoris, and
patients on oral anti-coagulants). Patients already on NSAIDs had to stop
their medication and switched to the study-medication after a wash-out pe-
riod of 7 days. The study was conducted according to the declaration of Hel-
sinki and received ethics approval in all centres. Each patient gave written
informed consent before participating in the study.STUDY DESIGNPatients with knee OA were randomized treated 4 weeks prior to knee re-
placement surgery with celecoxib 200 mg b.d. (n¼ 12), indomethacin 50 mg
b.d. (n¼ 8), or received no treatment (n¼ 8; controls). Because of its plate-
let-inhibiting effect, indomethacin-usage had to be stopped 3 days prior to op-
eration which was compensated for by a 3-day earlier start of medication and
because of the increased risk for GI adverse effects with the use of indometh-
acin, all patients on thismedication also received omeprazol (20 o.d.mg). Con-
trols did not use NSAIDs according to their medical records andwere informed
explicitly not to take an occasional NSAID in the last 4 weeks prior to operation.At joint replacement surgery, synovial tissue and cartilage with underlying
bone were obtained from femoral condyles and tibial plateaus. This tissue
was kept in phosphate buffered saline for less than 4 h and subsequently
processed under laminar ﬂow conditions at the UMCU. The investigators
who performed the experiments and analysis were blinded to the patients’
clinical data and medication use. All the cartilage present on the weight bear-
ing area of the joint was cut aseptically from the underlying bone. The slices
were cut into squares and weighted (range 5e15 mg, accuracy 0.1 mg).
Twenty-four samples were randomly selected the remaining sample were
discarded. Four of these randomly taken samples of each donor were ﬁxed
in 4% phosphate buffered formalin in 2% sucrose and stained with Safranin-
O fast greeneiron haematoxylin for histochemistry. The remaining 20 ran-
domly taken cartilage samples of each donor were used for biochemical
analysis of proteoglycan synthesis, -retention, -release, -content, prostaglan-
din-E2 (PGE2) production, and nitric oxide (NO) production. Additionally, four
synovial tissue samples from each donor were taken for determination of sy-
novial tissue derived pro-inﬂammatory/tissue destructive cytokine production
and matrix metalloproteinase (MMP) activity.HISTOCHEMISTRYFour randomly taken cartilage samples were graded for features of OA,
using the modiﬁed Mankin criteria33,34. Two observers blinded to the source
of the cartilage graded the cartilage and the averages of the two observers
and the four samples were taken as representative score of each donor.PROTEOGLYCAN ANALYSISAs a measure of the proteoglycan synthesis rate, the sulphate incorpora-
tion rate was determined over a 4-h period. Na2SO4
2 (DuPont NEX-041-H,
carrier free) 370 kBq was added to each 200 ml culture medium, consisting
of Dulbecco’s modiﬁed Eagle’s medium (DMEM), supplemented with
glutamine (2 mM), penicillin (100 IU/ml), streptomycin sulphate (100 mg/ml)
ascorbic acid (0.085 mM) and 10% heat inactivated pooled human male
ABþ serum. Samples were equilibrated for 1 h before adding 35SO4
2. After
the 4-h labelling period, the cartilage explants were washed three times for
45 min in culture medium under culture conditions and then cultured, individ-
ually in a 96-well round bottomed microtiter plate (200 ml culture medium/well
37C, 5% CO2 in air) for an additional period of 3 days. After this period
cartilage and culture medium were separated, snap frozen, and stored at
20C for no longer than 7 days.
For proteoglycan synthesis and -content, cartilage samples were digested
(2 h, 65C) in papain buffer as described before35. Papain digests were
diluted to the appropriate concentrations and glycosaminoglycans (GAGs)
were stained and precipitated with Alcian Blue dye solution36. The pellet
obtained after centrifugation (9000g, 10 min) was washed once (sodium
acetate (NaAc) buffer containing 0.1 M MgCl2) and subsequently dissolved
(sodium dodecyl sulphate (SDS)). The 35S radioactivity of the sample
was measured by liquid scintillation analysis after addition of Picoﬂuor-40
(Packard). 35SO4
2 incorporation was normalized to the speciﬁc activity of
the medium, labelling time, and wet weight of the cartilage samples. The pro-
teoglycan synthesis rate is expressed as nanomoles of sulphate incorpo-
rated per hour per gram wet weight of the cartilage (nmol/h/g). Blue
staining was quantiﬁed photometrically by the change in absorbance at
620 nm. Chondroitin sulphate (C4383; Sigma) was used as a reference.
Values were normalized to the wet weight of the cartilage and expressed
as milligrams of GAG per gram wet weight of cartilage (mg/g).
Release of newly formed proteoglycans, as a measure of retention of
these proteoglycans, and total proteoglycan release was determined in
culture medium. GAGs were precipitated from the 3-day culture medium
and stained with Alcian Blue36. As a measure of the release of newly formed
proteoglycans the 35S-radio-labelled GAGs were measured by liquid scintil-
lation analysis, normalized to the proteoglycan synthesis rate, and
expressed as percentage release of newly formed proteoglycans. For the
total release of proteoglycans blue staining was quantiﬁed photometrically
by the change in absorbance at 620 nm (chondroitin sulphate used as a ref-
erence). Values were normalized to the GAG content of the explants and
expressed as a percentage release.PGE2 AND NO DETERMINATIONPGE2 and NO were determined in the ex vivo 3-day culture medium.
PGE2 was determined by Enzyme Immuno Assay (EIA, Caymann Chemical)
and expressed as pg/ml/mg (wet weight) cartilage tissue. NO levels were
determined using the standard Griess reaction and expressed as mM/mg
(wet weight) of cartilage tissue.SYNOVIAL TISSUE ANALYSISFour synovial tissue samples (192 93 mg) from each donor were cul-
tured for 3 days in 4 ml culture medium. The supernatants of these cultures
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(IL-1b) and tumour necrosis factor-a (TNF-a) were determined by Enzyme
Linked Immuno Sorbent Assay (ELISA) and expressed as pg/ml/mg synovial
tissue. MMP activity was measured by use of a ﬂuorogenic MMP speciﬁc
substrate with a built in quencher TNO013-F (Dabcyl-Gaba-Pro-Arg-Gly-
Leu-Cys(Acetyl-Fluorescein)-Ala-Lys-NH2, measuring MMP-2, 9 and espe-
cially 13) as described before37 and expressed as relative ﬂuorescents units
(RFUs)/s/mg synovial tissue.CALCULATIONS AND STATISTICAL ANALYSISBecause of focal differences in composition and bioactivity of the knee
cartilage (speciﬁcally in case of severe OA) the results of 20 cartilage sam-
ples per parameter per patient (obtained at random and handled individually)
were averaged and taken as a representative value for the cartilage of that
patient. For cartilage histochemistry, the average of four samples was
used. Similarly, the biochemical results of the four synovial tissue samples
per patient (obtained at random and handled individually) were averaged
and taken as a representative value for the cartilage of that patient.
Means of the donors in each group S.E.M. are presented. Statistical eval-
uation of the effects of treatment was performed with an independent-sample
T test. P values less than or equal to 0.05 were considered statistically
signiﬁcant.ResultsBASELINE CHARACTERISTICSAverage age was similar for the different treatment groups
(Table I), but gender varied considerably. The average his-
tological grade of cartilage damage ranged from 4.5 to 4.8,
not statistically different between the groups (Table I). It
should be kept in mind that only the cartilage that could be
cut from the joint surfaces after replacement surgery was
used which was always hyaline cartilage. Thus in fact the
entire joint had a worse appearance than represented by
the modiﬁed Mankin score of the cartilage used. Figure 1
shows a representative photograph of the material used
and a light micrograph of cartilage as used for evaluation,
depicting the typical characteristics of OA cartilage including
loss of Safranin-O staining, ﬁssures and irregularities of the
articular surface, and disturbance of the chondrocyte distri-
bution (clusters of chondrocytes).EFFECTS OF NSAIDs ON PROTEOGLYCAN TURNOVERThe non-treated patients showed based on previous stud-
ies, a proteoglycan synthesis rate, -retention, -release, and
-content typical for osteoarthritic cartilage35 [Fig. 2(AeD)].
Patients who had used celecoxib for a period of 4 weeks
showed a statistically signiﬁcant higher proteoglycan synthe-
sis rate compared to the non-treated group (P< 0.05; indi-
cated by asterisks) and a higher synthesis rate comparedTable I
Baseline and histological characteristics for the different treatment
groups
Controls
(n¼ 8)
Indomethacin
(n¼ 8)
Celecoxib
(n¼ 12)
Age (years)* 65 2 69 3 67 3
Gender
(female/male)
8/0 5/3 10/2
Histological cartilage
damage (Mankin grade)*
4.8 0.4 4.8 0.5 4.5 0.3
*Age and histological grade of cartilage damage are presented
as means S.E.M., gender is presented as a female/male ratio.
There were no statistical signiﬁcant differences between different
groups regarding age, gender and histological grade of cartilage
damage.to the indomethacin group (P< 0.01; indicated by wickets).
In contrast, the indomethacin group showed a tendency to-
wards a lower proteoglycan synthesis rate compared to the
non-treated patients (ns). The increased proteoglycan syn-
thesis by celecoxib was accompanied by a better retention
of the newly formed proteoglycans; celecoxib had a dimin-
ished release of newly formed proteoglycans compared to
the untreated controls (P< 0.01), with indomethacin treat-
ment the same effect was found (P< 0.05) [Fig. 2(B)].
Also for the total release of proteoglycans, the newly
formed and the resident ones, signiﬁcant lower values
were found for the celecoxib (P< 0.01) treated patients
compared to the non-treated group. Indomethacin treatment
did not reveal a statistically signiﬁcant difference in total pro-
teoglycan release compared to the control group, although
on average similar effects were found [Fig. 2(C)].
Most interestingly, a treatment period of 4 weeks resulted
in a signiﬁcant increase in proteoglycan content in the
celecoxib group compared to the non-treated patients
(P< 0.05) and compared to the indomethacin group
(P< 0.05) [Fig. 2(D)]. In contrast, the indomethacin group
showed a tendency towards a lower proteoglycan content
compared to the non-treated patients (ns).EFFECTS OF NSAIDs ON PGE2 AND NO PRODUCTIONIn order to evaluate whether both NSAIDs were able to
modulate the enhanced COX-2 production of the cartilage,
the PGE2 production during the 3 days of ex vivo culture
was measured. As shown in Fig. 3(A), PGE2 production
was diminished for cartilage obtained from the two treated
groups when compared to the controls (P< 0.05 and
0.01, for indomethacin and celecoxib, respectively).
Figure 3(B) shows a NO production which is equally lower
in the two treated groups compared to the controls
(P< 0.01 and 0.001, respectively).INFLAMMATORY CYTOKINES AND MMP ACTIVITY BY
SYNOVIAL TISSUETo see whether the different NSAIDs had inﬂuenced the
synovial tissue, the inﬂammatory cytokines IL-1b and
TNF-a and the MMP activity of this tissue were measured.
Celecoxib treatment demonstrated a decrease in IL-1b
and TNF-a release (both P< 0.05), whereas indomethacin
treatment only decreased the IL-1b release (Table II).
Both treatments showed a tendency to reduce MMP activity
compared to the control group, although not statistically
signiﬁcant.Discussion
The purpose of this study was to evaluate the in vivo ef-
fect of celecoxib, a selective COX-2 inhibitor, compared to
a frequently used conventional NSAID indomethacin, on
human osteoarthritic cartilage, using detailed biochemical
ex vivo evaluation of the cartilage tissue. To our knowledge
this is the ﬁrst in vivo study showing e by use of ex vivo
evaluation e that celecoxib has a favourable effect on
proteoglycan turnover of human osteoarthritic cartilage.
Moreover, it is the ﬁrst time that the in vitro data on human
cartilage tissue in this respect3,28e30 have been veriﬁed in
vivo/ex vivo.
A great advantage of using this approach is the opportu-
nity to perform a full detailed biochemical analysis of the
articular cartilage while the treatment was given in vivo.
Fig. 1. Representative macroscopic and histological images of the osteoarthritic cartilage used. Representative example of plateau and con-
dylar cartilage obtained at joint replacement surgery (A) and light micrograph of this cartilage (B). Sections are stained with Safranin-O fast
greeneiron haematoxylin and graded for features of OA according to the slightly modiﬁed criteria described by Mankin et al., this speciﬁc
sample was scored 6.
485Osteoarthritis and Cartilage Vol. 17, No. 4A drawback is that in addition to the direct effects on carti-
lage (as evaluated thus far in vitro), there will be an effect on
synovial tissue inﬂammatory activity, with expectedly
indirect effects on cartilage. Moreover, the cartilage tissue
studied involves severely damaged (end stage disease)
tissue. Another drawback of the approach is that the condi-
tion of the cartilage before start of treatment is not known,
enabling only unpaired evaluation. On the other hand, it is
expected that the histochemical evaluation of the cartilage
after treatment is also representative of the cartilage condi-
tion before start of treatment, as it is not likely that the
histochemical grade will change signiﬁcantly in a relative
short period of 4 weeks.
Both NSAIDs were effective with respect to inhibition of
PGE2 production, as expected. The change in PGE2 pro-
duction induced by the two NSAIDs equals the decrease
in proteoglycan release. This corroborates the in vitro
ﬁndings where a strong correlation between release of
cartilage matrix proteoglycans and PGE2 has been
demonstrated38.
Also the NO levels in the present ex vivo experiments
show a decrease under the inﬂuence of celecoxib and indo-
methacin. Previous in vitro work has demonstrated an
inverse correlation between NO production by chondro-
cytes and proteoglycan synthesis rate. In these in vitro
experiments, selective COX-2 inhibition, however, had
hardly an effect on NO production and also only a marginal
inﬂuence on proteoglycan synthesis rate38. The beneﬁcial
effect on proteoglycan synthesis rate and on NO production
by celecoxib in the present study, therefore, contrasts the
previously reported in vitro results, and might, therefore,
be due to the indirect effects via the synovial inﬂammation.
Interestingly the inverse relation between NO production
and proteoglycan synthesis rate of cartilage asdemonstrated in vitro and found for this in vivo study for
the celecoxib treatment (decreased NO release with an
increased synthesis rate) was not found for indomethacin.
Due to indomethacin treatment, NO release decreased
but the synthesis rate was not enhanced. The absence of
an effect on proteoglycan synthesis rate may also explain
the absence of an effect on proteoglycan content. Appar-
ently additional mechanisms are involved. Interestingly in
this respect was to see that indomethacin, in contrast to
celecoxib, was unable to lower TNF-a release by synovial
tissue, a mechanism that could be involved. TNF-a has
been related to NO production previously38. The fact that
indomethacin also inhibits COX-1 might be involved as
well: an in vitro study showed that selective inhibition of
COX-1 with SC-560 resulted in an inhibited proteoglycan
synthesis while selective COX-2 inhibition with celecoxib
showed an increased proteoglycan synthesis29.
The effects of celecoxib on cartilage were all beneﬁcial as
was also observed after in vitro exposure of human
cartilage to celecoxib28e30. Previous research showed
a beneﬁcial effect of celecoxib on normal human cartilage
under the inﬂuence of IL-1b and TNF-a30,38. In addition
a beneﬁcial effect of celecoxib on human osteoarthritic car-
tilage, both early and late, was demonstrated29. Recently,
El Hajjaji et al. showed that celecoxib was able to increase
hyaluronan and proteoglycan synthesis and to diminish
hyaluronan and proteoglycan release of end stage osteoar-
thritic cartilage obtained at joint replacement surgery. In the
present study the supposed chondroprotective and even
-reparative effects of celecoxib are conﬁrmed in vivo. In
contrast, no signiﬁcant differences were found in the indo-
methacin group compared to no treatment with respect to
synthesis rate and content of proteoglycans. On the con-
trary, a tendency towards a negative effect was found.
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Fig. 2. Effects on proteoglycan turnover and content of OA cartilage. Proteoglycan synthesis rate (A), percentage release of newly
formed proteoglycans (B), percentage total proteoglycan release (C) and proteoglycan content (D) are given. The results are presented
as means S.E.M. Statistical differences for the effect of an NSAID compared to non-treated or treated patients are calculated by non-
parametric non-paired analysis. Asterisks (*) indicate statistical signiﬁcant differences compared to controls, wickets (#) indicate statis-
tical signiﬁcant differences between treatment groups.
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Fig. 3. Effects on PGE2 and NO production. Production of PGE2 (A) and NO (B) measured in the 3-day cartilage culture media of the
three treatment groups is given. The results are presented as means S.E.M. Statistical differences for the effect of an NSAID
compared to non-treated or treated patients are calculated by non-parametric non-paired analysis.
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Table II
Inflammatory cytokines and MMP activity by synovial tissue
Controls
(n¼ 8)
Indomethacin
(n¼ 8)
Celecoxib
(n¼ 12)
IL-1b
(pg/ml/mg tissue)*
14.8 5.6 1.9 1.1y 1.9 1.1y
TNF-a
(pg/ml/mg tissue)*
1.5 0.9 1.8 0.8 0.3 0.1y
MMP activity
(RFU/s/mg tissue)*
0.07 0.01 0.04 0.02 0.04 0.01
*Ex vivo IL-1b levels, TNF-a levels, and MMP activity of synovial
tissue of the three treatment groups, presented as mean S.E.M.
yRepresents statistical signiﬁcant difference compared to
controls.
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a signiﬁcant difference for both parameters.
It cannot be ruled out that the lack of a clear beneﬁcial
response of indomethacin is due to the fact that indometh-
acin was stopped 3 days prior to surgery, whereas cele-
coxib was given until the day of surgery. Because of the
effects of indomethacin on coagulation, however, it was
not feasible to continue this medication until the day of sur-
gery. With a relatively short average half-life time, the
effects of indomethacin on the cartilage might partly have
been vanished during the last 3 days. However, the PGE2
levels of the indomethacin treated patients as well as pro-
teoglycan release were decreased compared to non-treated
patients indicating efﬁcacy of indomethacin at those levels.
But different lag times between cessation of treatment and
loss of efﬁcacy for the different parameters cannot be ruled
out. Further research is needed, including the evaluation of
celecoxib treatment until 3 days before surgery. In addition,
more commonly used NSAIDs and other Coxibs as compar-
ators of celecoxib need to be studied.
There have not been many recent studies on the direct
effects of NSAIDs on cartilage. Previous in vitro work has
shown that several types of NSAIDs inhibit the synthesis
of proteoglycans and collagens by chondrocytes, and there-
fore, have a negative effect on cartilage20,39. A more recent
study on diclofenac, a non-selective COX inhibitor that pre-
viously has been demonstrated in vitro to have negative
effects on cartilage was studied by Reijman et al.40 in
vivo. Patients using diclofenac showed an accelerated pro-
gression of hip and knee OA compared to patients using
ibuprofen, naproxen or piroxicam. But whether this was
caused by a deleterious effect on cartilage or by enhanced
mechanical loading because of the analgesic effects
remains to be established.
There is a lot of debate whether all patients considered
for joint replacement indeed need surgical intervention or
whether alternative medical treatment is still possible41. In
our study most of the patients included did not use NSAIDs
for their OA, supporting this observation. In this respect also
in end stage OA treatment with celecoxib may have its ben-
eﬁt. On the other hand it is proof of concept: in our in vitro
studies we demonstrated beneﬁcial effects on end stage
OA cartilage and on less severe damaged (pre-clinical
OA) cartilage29. As such the present outcome might be
extrapolated to less severe stages of OA.
The recent recognition of the increased risk for cardiovas-
cular side-effects with the use of selective and non-selective
NSAIDs has put a new light on the use of selective COX-2
inhibitors in particular and all NSAIDs in general. Further
research needs to clarify the risk of the individual NSAIDs
at the cardiovascular level, in relation to the other side-effectsand their clinical efﬁcacy. In the meantime the risk and ben-
eﬁts of different NSAIDs should be considered very carefully
in the treatment of OA patients. In this consideration, the
present results demonstrating the beneﬁcial effects of
celecoxib on cartilage in contrast to the neutral to adverse
effects of indomethacin should be kept in mind when making
a decision in prescribing analgesics in OA, a disease with
intrinsic cartilage damage, not primarily inﬂammation driven,
especially when long-term use is needed.
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